{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:08:00Z","timestamp":1791068880866,"version":"4.1.0"},"reference-count":164,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Northwest Cancer Research UK and Bloom Appeal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,3,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Monoallelic deletion of the short arm of chromosome 17 (del17p) is a recurrent abnormality in cancers with poor outcomes. Best studied in relation to haematological malignancies, associated functional outcomes are attributed mainly to loss and\/or dysfunction of <jats:italic>TP53<\/jats:italic>, which is located at 17p13.1, but the wider impact of deletion of other genes located on 17p is poorly understood. 17p is one of the most gene-dense regions of the genome and includes tumour suppressor genes additional to <jats:italic>TP53<\/jats:italic>, genes essential for cell survival and proliferation, as well as small and long non-coding RNAs. In this review we utilise a data-driven approach to demarcate the extent of 17p deletion in multiple cancers and identify a common loss-of-function gene signature. We discuss how the resultant loss of heterozygosity (LOH) and haploinsufficiency may influence cell behaviour but also identify vulnerabilities that can potentially be exploited therapeutically. Finally, we highlight how emerging animal and isogenic cell line models of del17p can provide critical biological insights for cancer cell behaviour.<\/jats:p>","DOI":"10.1038\/s41388-025-03300-8","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T14:54:14Z","timestamp":1739890454000},"page":"637-651","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Deletion of 17p in cancers: Guilt by (p53) association"],"prefix":"10.1038","volume":"44","author":[{"given":"Francisca","family":"van Kampen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1688-6023","authenticated-orcid":false,"given":"Abigail","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Soul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5464-9006","authenticated-orcid":false,"given":"Aditi","family":"Kanhere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2490-2740","authenticated-orcid":false,"given":"Mark A.","family":"Glenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Pettitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5300-1360","authenticated-orcid":false,"given":"Nagesh","family":"Kalakonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7410-9004","authenticated-orcid":false,"given":"Joseph R.","family":"Slupsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"3300_CR1","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1158\/0008-5472.CAN-15-2198","volume":"76","author":"SJ Murphy","year":"2016","unstructured":"Murphy SJ, Hart SN, Halling GC, Johnson SH, Smadbeck JB, Drucker T, et al. Integrated genomic analysis of pancreatic ductal adenocarcinomas reveals genomic rearrangement events as significant drivers of disease. Cancer Res. 2016;76:749\u201361.","journal-title":"Cancer Res"},{"key":"3300_CR2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature17157","volume":"531","author":"Y Liu","year":"2016","unstructured":"Liu Y, Chen C, Xu Z, Scuoppo C, Rillahan CD, Gao J, et al. Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. Nature. 2016;531:471\u20135.","journal-title":"Nature"},{"key":"3300_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41576-019-0171-x","volume":"21","author":"U Ben-David","year":"2020","unstructured":"Ben-David U, Amon A. Context is everything: aneuploidy in cancer. Nat Rev Genet. 2020;21:44\u201362.","journal-title":"Nat Rev Genet"},{"key":"3300_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc6894","volume":"13","author":"Y Li","year":"2021","unstructured":"Li Y, Sun Y, Kulke M, Hechler T, Van der Jeught K, Dong T, et al. Targeted immunotherapy for HER2-low breast cancer with 17p loss. Sci Transl Med. 2021;13:eabc6894.","journal-title":"Sci Transl Med"},{"key":"3300_CR5","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1038\/sj.onc.1210832","volume":"27","author":"T Harada","year":"2008","unstructured":"Harada T, Chelala C, Bhakta V, Chaplin T, Caulee K, Baril P, et al. Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. Oncogene. 2008;27:1951\u201360.","journal-title":"Oncogene"},{"key":"3300_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/gcc.2870120204","volume":"12","author":"G Bardi","year":"1995","unstructured":"Bardi G, Sukhikh T, Pandis N, Fenger C, Kronborg O, Heim S. Karyotypic characterization of colorectal adenocarcinomas. Genes Chromosomes Cancer. 1995;12:97\u2013109.","journal-title":"Genes Chromosomes Cancer"},{"key":"3300_CR7","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/path.2712","volume":"221","author":"JM Sayagu\u00e9s","year":"2010","unstructured":"Sayagu\u00e9s JM, Abad Mdel M, Melchor HB, Guti\u00e9rrez ML, Gonz\u00e1lez-Gonz\u00e1lez M, Jensen E, et al. Intratumoural cytogenetic heterogeneity of sporadic colorectal carcinomas suggests several pathways to liver metastasis. J Pathol. 2010;221:308\u201319.","journal-title":"J Pathol"},{"key":"3300_CR8","first-page":"4259","volume":"24","author":"M Chmara","year":"2004","unstructured":"Chmara M, Wozniak A, Ochman K, Kobierska G, Dziadziuszko R, Sosinska-Mielcarek K, et al. Loss of heterozygosity at chromosomes 3p and 17p in primary non-small cell lung cancer. Anticancer Res. 2004;24:4259\u201363.","journal-title":"Anticancer Res"},{"key":"3300_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06811-z","volume":"9","author":"Y Li","year":"2018","unstructured":"Li Y, Liu Y, Xu H, Jiang G, Van der Jeught K, Fang Y, et al. Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II. Nat Commun 2018;9:4394.","journal-title":"Nat Commun"},{"key":"3300_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-2-32","volume":"2","author":"SM Wilting","year":"2009","unstructured":"Wilting SM, Smeets SJ, Snijders PJ, van Wieringen WN, van de Wiel MA, Meijer GA, et al. Genomic profiling identifies common HPV-associated chromosomal alterations in squamous cell carcinomas of cervix and head and neck. BMC Med Genomics. 2009;2:32.","journal-title":"BMC Med Genomics"},{"key":"3300_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.8","volume":"3","author":"TJ Kipps","year":"2017","unstructured":"Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017;3:17008.","journal-title":"Nat Rev Dis Primers"},{"key":"3300_CR12","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1200\/JCO.2012.46.2598","volume":"31","author":"H Avet-Loiseau","year":"2013","unstructured":"Avet-Loiseau H, Hulin C, Campion L, Rodon P, Marit G, Attal M, et al. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du my\u00e9lome experience. J Clin Oncol. 2013;31:2806\u20139.","journal-title":"J Clin Oncol"},{"key":"3300_CR13","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679\u201390.","journal-title":"Nat Med"},{"key":"3300_CR14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI153283","volume":"132","author":"S Yi","year":"2022","unstructured":"Yi S, Yan Y, Jin M, Bhattacharya S, Wang Y, Wu Y, et al. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J Clin Invest. 2022;132:e153283.","journal-title":"J Clin Invest"},{"key":"3300_CR15","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164\u201374.","journal-title":"Lancet"},{"key":"3300_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/gcc.22692","volume":"58","author":"YY Yuan","year":"2019","unstructured":"Yuan YY, Zhu HY, Wu JZ, Xia Y, Liang JH, Wu W, et al. The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2019;58:43\u201351.","journal-title":"Genes Chromosomes Cancer"},{"key":"3300_CR17","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1.","journal-title":"Sci Signal"},{"key":"3300_CR18","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1158\/1078-0432.CCR-16-0594","volume":"23","author":"L Yu","year":"2017","unstructured":"Yu L, Kim HT, Kasar S, Benien P, Du W, Hoang K, et al. Survival of del17p CLL depends on genomic complexity and somatic mutation. Clin Cancer Res. 2017;23:735\u201345.","journal-title":"Clin Cancer Res"},{"key":"3300_CR19","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1056\/NEJMoa073770","volume":"357","author":"ML Poeta","year":"2007","unstructured":"Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357:2552\u201361.","journal-title":"N Engl J Med"},{"key":"3300_CR20","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2008-04-154070","volume":"112","author":"T Zenz","year":"2008","unstructured":"Zenz T, Kr\u00f6ber A, Scherer K, H\u00e4be S, B\u00fchler A, Benner A, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood. 2008;112:3322\u20139.","journal-title":"Blood"},{"key":"3300_CR21","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.1158\/1078-0432.CCR-20-4890","volume":"27","author":"C Brieghel","year":"2021","unstructured":"Brieghel C, Aarup K, Torp MH, Andersen MA, Yde CW, Tian X, et al. Clinical outcomes in patients with multi-Hit TP53 chronic lymphocytic leukemia treated with ibrutinib. Clin Cancer Res. 2021;27:4531\u20138.","journal-title":"Clin Cancer Res"},{"key":"3300_CR22","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41375-023-01845-9","volume":"37","author":"R Bomben","year":"2023","unstructured":"Bomben R, Rossi FM, Vit F, Bittolo T, Zucchetto A, Papotti R, et al. Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study. Leukemia. 2023;37:914\u20138.","journal-title":"Leukemia"},{"key":"3300_CR23","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1182\/blood.2020010536","volume":"138","author":"AS Kittai","year":"2021","unstructured":"Kittai AS, Miller C, Goldstein D, Huang Y, Abruzzo LV, Beckwith K, et al. The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. Blood. 2021;138:2372\u201382.","journal-title":"Blood"},{"key":"3300_CR24","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/gcc.22277","volume":"54","author":"I Salaverria","year":"2015","unstructured":"Salaverria I, Mart\u00edn-Garcia D, L\u00f3pez C, Clot G, Garc\u00eda-Aragon\u00e9s M, Navarro A, et al. Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2015;54:668\u201380.","journal-title":"Genes Chromosomes Cancer"},{"key":"3300_CR25","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/nature04689","volume":"440","author":"MC Zody","year":"2006","unstructured":"Zody MC, Garber M, Adams DJ, Sharpe T, Harrow J, Lupski JR, et al. DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage. Nature. 2006;440:1045\u20139.","journal-title":"Nature"},{"key":"3300_CR26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.gene.2013.09.044","volume":"532","author":"CP Chen","year":"2013","unstructured":"Chen CP, Chang TY, Guo WY, Wu PC, Wang LK, Chern SR, et al. Chromosome 17p13.3 deletion syndrome: aCGH characterization, prenatal findings and diagnosis, and literature review. Gene. 2013;532:152\u20139.","journal-title":"Gene"},{"key":"3300_CR27","doi-asserted-by":"crossref","unstructured":"Rinaldi B, Villa R, Sironi A, Garavelli L, Finelli P, Bedeschi MF. Smith-Magenis Syndrome-clinical review, biological background and related disorders. Genes. 2022;13.","DOI":"10.3390\/genes13020335"},{"key":"3300_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-9-38","volume":"9","author":"BW van Paassen","year":"2014","unstructured":"van Paassen BW, van der Kooi AJ, van Spaendonck-Zwarts KY, Verhamme C, Baas F, de Visser M. PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and Hereditary Neuropathy with liability to Pressure Palsies. Orphanet J Rare Dis. 2014;9:38.","journal-title":"Orphanet J Rare Dis"},{"key":"3300_CR29","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1684\/epd.2022.1416","volume":"24","author":"N Yamamoto","year":"2022","unstructured":"Yamamoto N, Okazaki S, Kuki I, Yamada N, Nagase S, Nukui M, et al. Possible critical region associated with late-onset spasms in 17p13.1-p13.2 microdeletion syndrome: a report of two new cases and review of the literature. Epileptic Disord. 2022;24:567\u201371.","journal-title":"Epileptic Disord"},{"key":"3300_CR30","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/ajmg.a.33316","volume":"152a","author":"C Schluth-Bolard","year":"2010","unstructured":"Schluth-Bolard C, Sanlaville D, Labalme A, Till M, Morin I, Touraine R, et al. 17p13.1 microdeletion involving the TP53 gene in a boy presenting with mental retardation but no tumor. Am J Med Genet A. 2010;152a:1278\u201382.","journal-title":"Am J Med Genet A"},{"key":"3300_CR31","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.cell.2015.11.015","volume":"163","author":"T Hart","year":"2015","unstructured":"Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, et al. High-Resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell. 2015;163:1515\u201326.","journal-title":"Cell"},{"key":"3300_CR32","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.cell.2017.07.005","volume":"170","author":"ER McDonald 3rd","year":"2017","unstructured":"McDonald ER 3rd, de Weck A, Schlabach MR, Billy E, Mavrakis KJ, Hoffman GR, et al. Project DRIVE: A compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening. Cell. 2017;170:577\u201392.e10.","journal-title":"Cell"},{"key":"3300_CR33","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"3300_CR34","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.1182\/blood-2012-04-423517","volume":"120","author":"J Edelmann","year":"2012","unstructured":"Edelmann J, Holzmann K, Miller F, Winkler D, B\u00fchler A, Zenz T, et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood. 2012;120:4783\u201394.","journal-title":"Blood"},{"key":"3300_CR35","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1182\/blood-2005-04-1399","volume":"106","author":"S Bea","year":"2005","unstructured":"Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005;106:3183\u201390.","journal-title":"Blood"},{"key":"3300_CR36","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/gcc.20899","volume":"50","author":"KD Boyd","year":"2011","unstructured":"Boyd KD, Ross FM, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ, et al. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. Genes Chromosomes Cancer. 2011;50:765\u201374.","journal-title":"Genes Chromosomes Cancer"},{"key":"3300_CR37","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1182\/blood-2009-03-210591","volume":"114","author":"CS Tam","year":"2009","unstructured":"Tam CS, Shanafelt TD, Wierda WG, Abruzzo LV, Van Dyke DL, O\u2019Brien S, et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood. 2009;114:957\u201364.","journal-title":"Blood"},{"key":"3300_CR38","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1038\/leu.2010.208","volume":"24","author":"T Zenz","year":"2010","unstructured":"Zenz T, Vollmer D, Trbusek M, Smardova J, Benner A, Soussi T, et al. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia. 2010;24:2072\u20139.","journal-title":"Leukemia"},{"key":"3300_CR39","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1038\/sj.onc.1209387","volume":"25","author":"CJ Lynch","year":"2006","unstructured":"Lynch CJ, Milner J. Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency. Oncogene. 2006;25:3463\u201370.","journal-title":"Oncogene"},{"key":"3300_CR40","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1038\/leu.2014.102","volume":"28","author":"PJ Teoh","year":"2014","unstructured":"Teoh PJ, Chung TH, Sebastian S, Choo SN, Yan J, Ng SB, et al. p53 haploinsufficiency and functional abnormalities in multiple myeloma. Leukemia. 2014;28:2066\u201374.","journal-title":"Leukemia"},{"key":"3300_CR41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/bjh.12092","volume":"160","author":"K Lin","year":"2013","unstructured":"Lin K, Lane B, Carter A, Johnson GG, Onwuazor O, Oates M, et al. The gene expression signature associated with TP53 mutation\/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes on chromosome 17p. Br J Haematol. 2013;160:53\u201362.","journal-title":"Br J Haematol"},{"key":"3300_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25359-z","volume":"12","author":"LN Redman-Rivera","year":"2021","unstructured":"Redman-Rivera LN, Shaver TM, Jin H, Marshall CB, Schafer JM, Sheng Q, et al. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes. Nat Commun. 2021;12:5184.","journal-title":"Nat Commun"},{"key":"3300_CR43","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1054\/bjoc.2000.1292","volume":"83","author":"EC Burt","year":"2000","unstructured":"Burt EC, James LA, Greaves MJ, Birch JM, Boyle JM, Varley JM. Genomic alterations associated with loss of heterozygosity for TP53 in Li-Fraumeni syndrome fibroblasts. Br J Cancer. 2000;83:467\u201372.","journal-title":"Br J Cancer"},{"key":"3300_CR44","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/bjc.1998.364","volume":"77","author":"JM Boyle","year":"1998","unstructured":"Boyle JM, Mitchell EL, Greaves MJ, Roberts SA, Tricker K, Burt E, et al. Chromosome instability is a predominant trait of fibroblasts from Li-Fraumeni families. Br J Cancer 1998;77:2181\u201392.","journal-title":"Br J Cancer"},{"key":"3300_CR45","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549\u201356.","journal-title":"Nat Med"},{"key":"3300_CR46","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/codi.15946","volume":"24","author":"MM Golas","year":"2022","unstructured":"Golas MM, Gunawan B, Cakir M, Cameron S, Enders C, Liersch T, et al. Evolutionary patterns of chromosomal instability and mismatch repair deficiency in proximal and distal colorectal cancer. Colorectal Dis. 2022;24:157\u201376.","journal-title":"Colorectal Dis"},{"key":"3300_CR47","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/ijc.30222","volume":"139","author":"G Lazarian","year":"2016","unstructured":"Lazarian G, Tausch E, Eclache V, Sebaa A, Bianchi V, Letestu R, et al. TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes. Int J Cancer. 2016;139:1759\u201363.","journal-title":"Int J Cancer"},{"key":"3300_CR48","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s13238-022-00914-6","volume":"13","author":"S Zhang","year":"2022","unstructured":"Zhang S, Wu Z, Shi Y, Wang S, Ren J, Yu Z, et al. FTO stabilizes MIS12 and counteracts senescence. Protein Cell. 2022;13:954\u201360.","journal-title":"Protein Cell"},{"key":"3300_CR49","first-page":"1513","volume":"27","author":"N Temime-Smaali","year":"2008","unstructured":"Temime-Smaali N, Guittat L, Wenner T, Bayart E, Douarre C, Gomez D, et al. Topoisomerase IIIalpha is required for normal proliferation and telomere stability in alternative lengthening of telomeres. EMBO J. 2008;27:1513\u201324.","journal-title":"EMBO J"},{"key":"3300_CR50","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/bjh.13995","volume":"174","author":"S Medves","year":"2016","unstructured":"Medves S, Auchter M, Chambeau L, Gazzo S, Poncet D, Grangier B, et al. A high rate of telomeric sister chromatid exchange occurs in chronic lymphocytic leukaemia B-cells. Br J Haematol. 2016;174:57\u201370.","journal-title":"Br J Haematol"},{"key":"3300_CR51","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1182\/blood-2010-02-272104","volume":"116","author":"TT Lin","year":"2010","unstructured":"Lin TT, Letsolo BT, Jones RE, Rowson J, Pratt G, Hewamana S, et al. Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Blood. 2010;116:1899\u2013907.","journal-title":"Blood"},{"key":"3300_CR52","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1038\/s41375-019-0423-y","volume":"33","author":"L Escudero","year":"2019","unstructured":"Escudero L, Cleal K, Ashelford K, Fegan C, Pepper C, Liddiard K, et al. Telomere fusions associate with coding sequence and copy number alterations in CLL. Leukemia. 2019;33:2093\u20137.","journal-title":"Leukemia"},{"key":"3300_CR53","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ng0198-018","volume":"18","author":"UM Martens","year":"1998","unstructured":"Martens UM, Zijlmans JM, Poon SS, Dragowska W, Yui J, Chavez EA, et al. Short telomeres on human chromosome 17p. Nat Genet. 1998;18:76\u201380.","journal-title":"Nat Genet"},{"key":"3300_CR54","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1158\/1055-9965.EPI-05-0837","volume":"15","author":"JC Finley","year":"2006","unstructured":"Finley JC, Reid BJ, Odze RD, Sanchez CA, Galipeau P, Li X, et al. Chromosomal instability in Barrett\u2019s esophagus is related to telomere shortening. Cancer Epidemiol Biomarkers Prev. 2006;15:1451\u20137.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"3300_CR55","doi-asserted-by":"publisher","first-page":"8317","DOI":"10.1007\/s13277-015-3556-2","volume":"36","author":"P Dos Santos","year":"2015","unstructured":"Dos Santos P, Panero J, Palau Nagore V, Stanganelli C, Bezares RF, Slavutsky I. Telomere shortening associated with increased genomic complexity in chronic lymphocytic leukemia. Tumour Biol. 2015;36:8317\u201324.","journal-title":"Tumour Biol"},{"key":"3300_CR56","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1080\/10428194.2017.1390236","volume":"59","author":"D Steinbrecher","year":"2018","unstructured":"Steinbrecher D, Jebaraj BMC, Schneider C, Edelmann J, Cymbalista F, Leblond V, et al. Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome. Leuk Lymphoma. 2018;59:1614\u201323.","journal-title":"Leuk Lymphoma"},{"key":"3300_CR57","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41375-019-0446-4","volume":"33","author":"BMC Jebaraj","year":"2019","unstructured":"Jebaraj BMC, Tausch E, Landau DA, Bahlo J, Robrecht S, Taylor-Weiner AN, et al. Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. Leukemia. 2019;33:2183\u201394.","journal-title":"Leukemia"},{"key":"3300_CR58","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/gcc.22171","volume":"53","author":"M Hoxha","year":"2014","unstructured":"Hoxha M, Fabris S, Agnelli L, Bollati V, Cutrona G, Matis S, et al. Relevance of telomere\/telomerase system impairment in early stage chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2014;53:612\u201321.","journal-title":"Genes Chromosomes Cancer"},{"key":"3300_CR59","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrm.2016.171","volume":"18","author":"J Maciejowski","year":"2017","unstructured":"Maciejowski J, de Lange T. Telomeres in cancer: tumour suppression and genome instability. Nat Rev Mol Cell Biol. 2017;18:175\u201386.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3300_CR60","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1128\/MCB.20.2.648-655.2000","volume":"20","author":"B Zheng","year":"2000","unstructured":"Zheng B, Sage M, Sheppeard EA, Jurecic V, Bradley A. Engineering mouse chromosomes with Cre-loxP: range, efficiency, and somatic applications. Mol Cell Biol. 2000;20:648\u201355.","journal-title":"Mol Cell Biol"},{"key":"3300_CR61","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41586-023-06266-3","volume":"619","author":"J Shih","year":"2023","unstructured":"Shih J, Sarmashghi S, Zhakula-Kostadinova N, Zhang S, Georgis Y, Hoyt SH, et al. Cancer aneuploidies are shaped primarily by effects on tumour fitness. Nature. 2023;619:793\u2013800.","journal-title":"Nature"},{"key":"3300_CR62","doi-asserted-by":"publisher","first-page":"D970","DOI":"10.1093\/nar\/gks937","volume":"41","author":"M Zhao","year":"2012","unstructured":"Zhao M, Sun J, Zhao Z. TSGene: a web resource for tumor suppressor genes. Nucleic Acids Res. 2012;41:D970\u2013D6.","journal-title":"Nucleic Acids Res"},{"key":"3300_CR63","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ydbio.2021.02.012","volume":"476","author":"G Morata","year":"2021","unstructured":"Morata G. Cell competition: a historical perspective. Dev Biol. 2021;476:33\u201340.","journal-title":"Dev Biol"},{"key":"3300_CR64","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3324\/haematol.2010.023697","volume":"95","author":"L Laurence","year":"2010","unstructured":"Laurence L, Marion E, Val\u00e9rie T, Thierry S, Soraya W, Steven R, et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica. 2010;95:1973\u20136.","journal-title":"Haematologica"},{"key":"3300_CR65","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/leu.2014.144","volume":"29","author":"A Kurtovic-Kozaric","year":"2015","unstructured":"Kurtovic-Kozaric A, Przychodzen B, Singh J, Konarska MM, Clemente MJ, Otrock ZK, et al. PRPF8 defects cause missplicing in myeloid malignancies. Leukemia. 2015;29:126\u201336.","journal-title":"Leukemia"},{"key":"3300_CR66","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/ng1587","volume":"37","author":"Y Wang","year":"2005","unstructured":"Wang Y, Putnam CD, Kane MF, Zhang W, Edelmann L, Russell R, et al. Mutation in Rpa1 results in defective DNA double-strand break repair, chromosomal instability and cancer in mice. Nat Genet. 2005;37:750\u20135.","journal-title":"Nat Genet"},{"key":"3300_CR67","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1158\/0008-5472.CAN-23-0628","volume":"83","author":"J Murai","year":"2023","unstructured":"Murai J, Pommier Y. BRCAness, Homologous recombination deficiencies, and synthetic lethality. Cancer Res. 2023;83:1173\u20134.","journal-title":"Cancer Res"},{"key":"3300_CR68","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc4517","volume":"6","author":"A Hsieh","year":"2020","unstructured":"Hsieh A, Pitarresi JR, Lerner J, Donahue G, Hsiehchen D, Rustgi AK, et al. Growth of pancreatic cancers with hemizygous chromosomal 17p loss of MYBBP1A can be preferentially targeted by PARP inhibitors. Sci Adv. 2020;6:eabc4517.","journal-title":"Sci Adv"},{"key":"3300_CR69","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2159-8290.CD-20-0336","volume":"11","author":"M Chen","year":"2021","unstructured":"Chen M, Chen X, Li S, Pan X, Gong Y, Zheng J, et al. An epigenetic mechanism underlying chromosome 17p deletion-driven tumorigenesis. Cancer Discov. 2021;11:194\u2013207.","journal-title":"Cancer Discov"},{"key":"3300_CR70","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1158\/0008-5472.CAN-08-4097","volume":"69","author":"L Hu","year":"2009","unstructured":"Hu L, Zhu YT, Qi C, Zhu YJ. Identification of Smyd4 as a potential tumor suppressor gene involved in breast cancer development. Cancer Res. 2009;69:4067\u201372.","journal-title":"Cancer Res"},{"key":"3300_CR71","doi-asserted-by":"publisher","first-page":"6097","DOI":"10.3390\/ijms25116097","volume":"25","author":"BL Olivera Santana","year":"2024","unstructured":"Olivera Santana BL, de Loyola MB, Gualberto ACM, Pittella-Silva F. Genetic alterations of SMYD4 in solid tumors using integrative multi-platform analysis. Int J Mol Sci. 2024;25:6097.","journal-title":"Int J Mol Sci"},{"key":"3300_CR72","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/emboj.2008.85","volume":"27","author":"A Weber","year":"2008","unstructured":"Weber A, Marquardt J, Elzi D, Forster N, Starke S, Glaum A, et al. Zbtb4 represses transcription of P21CIP1 and controls the cellular response to p53 activation. EMBO J. 2008;27:1563\u201374.","journal-title":"EMBO J"},{"key":"3300_CR73","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1182\/blood.2023022777","volume":"143","author":"A Gulla","year":"2024","unstructured":"Gulla A, Morelli E, Johnstone M, Turi M, Samur MK, Botta C, et al. Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma. Blood. 2024;143:2612\u201326.","journal-title":"Blood"},{"key":"3300_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s12863-015-0238-4","volume":"16","author":"C Hedberg Oldfors","year":"2015","unstructured":"Hedberg Oldfors C, Dios DG, Linder A, Visuttijai K, Samuelson E, Karlsson S, et al. Analysis of an independent tumor suppressor locus telomeric to Tp53 suggested Inpp5k and Myo1c as novel tumor suppressor gene candidates in this region. BMC Genet. 2015;16:80.","journal-title":"BMC Genet"},{"key":"3300_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10:1523.","journal-title":"Nat Commun"},{"key":"3300_CR76","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.mito.2016.09.001","volume":"31","author":"MA Ogasawara","year":"2016","unstructured":"Ogasawara MA, Liu J, Pelicano H, Hammoudi N, Croce CM, Keating MJ, et al. Alterations of mitochondrial biogenesis in chronic lymphocytic leukemia cells with loss of p53. Mitochondrion. 2016;31:33\u20139.","journal-title":"Mitochondrion"},{"key":"3300_CR77","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1200\/JCO.2005.02.568","volume":"23","author":"DL Kienle","year":"2005","unstructured":"Kienle DL, Korz C, Hosch B, Benner A, Mertens D, Habermann A, et al. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. J Clin Oncol. 2005;23:3780\u201392.","journal-title":"J Clin Oncol"},{"key":"3300_CR78","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1038\/s41375-021-01149-w","volume":"35","author":"T Baumann","year":"2021","unstructured":"Baumann T, Moia R, Gaidano G, Delgado J, Condoluci A, Villamor N, et al. Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients. Leukemia. 2021;35:2325\u201331.","journal-title":"Leukemia"},{"key":"3300_CR79","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.3390\/cancers13184682","volume":"13","author":"J Lia\u00f1o-Pons","year":"2021","unstructured":"Lia\u00f1o-Pons J, Arsenian-Henriksson M, Le\u00f3n J. The multiple faces of MNT and its role as a MYC modulator. Cancers. 2021;13:4682.","journal-title":"Cancers"},{"key":"3300_CR80","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.3390\/cancers12123546","volume":"12","author":"F Niu","year":"2020","unstructured":"Niu F, Dzikiewicz-Krawczyk A, Koerts J, de Jong D, Wijenberg L, Fernandez Hernandez M, et al. MiR-378a-3p is critical for Burkitt lymphoma cell growth. Cancers. 2020;12:3546.","journal-title":"Cancers"},{"key":"3300_CR81","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.3390\/cells11244087","volume":"11","author":"EV Prochownik","year":"2022","unstructured":"Prochownik EV, Wang H. Normal and neoplastic growth suppression by the extended Myc network. Cells. 2022;11:4087.","journal-title":"Cells"},{"key":"3300_CR82","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.bbrc.2011.04.117","volume":"409","author":"Z Xing","year":"2011","unstructured":"Xing Z, Tang X, Gao Y, Da L, Song H, Wang S, et al. The human LIS1 is downregulated in hepatocellular carcinoma and plays a tumor suppressor function. Biochem Biophys Res Commun. 2011;409:193\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"3300_CR83","doi-asserted-by":"publisher","first-page":"11142","DOI":"10.1111\/jcmm.17036","volume":"25","author":"Q Jin","year":"2021","unstructured":"Jin Q, Cheng M, Xia X, Han Y, Zhang J, Cao P, et al. Down-regulation of MYH10 driven by chromosome 17p13.1 deletion promotes hepatocellular carcinoma metastasis through activation of the EGFR pathway. J Cell Mol Med. 2021;25:11142\u201356.","journal-title":"J Cell Mol Med"},{"key":"3300_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36400-8","volume":"14","author":"Z Luo","year":"2023","unstructured":"Luo Z, Xin D, Liao Y, Berry K, Ogurek S, Zhang F, et al. Loss of phosphatase CTDNEP1 potentiates aggressive medulloblastoma by triggering MYC amplification and genomic instability. Nat Commun. 2023;14:762.","journal-title":"Nat Commun"},{"key":"3300_CR85","doi-asserted-by":"publisher","first-page":"e722","DOI":"10.1097\/HS9.0000000000000722","volume":"6","author":"K Kluckova","year":"2022","unstructured":"Kluckova K, Clear AJ, D\u2019Avola A, Rassenti LZ, Kipps TJ, Gribben JG, et al. B-cell receptor signaling induced metabolic alterations in chronic lymphocytic leukemia can be partially bypassed by TP53 abnormalities. Hemasphere. 2022;6:e722.","journal-title":"Hemasphere"},{"key":"3300_CR86","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498\u2013504.","journal-title":"Genome Res"},{"key":"3300_CR87","doi-asserted-by":"publisher","first-page":"e13984","DOI":"10.1371\/journal.pone.0013984","volume":"5","author":"D Merico","year":"2010","unstructured":"Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation. PLoS ONE. 2010;5:e13984.","journal-title":"PLoS ONE"},{"key":"3300_CR88","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1084\/jem.20150489","volume":"212","author":"A Mehta","year":"2015","unstructured":"Mehta A, Mann M, Zhao JL, Marinov GK, Majumdar D, Garcia-Flores Y, et al. The microRNA-212\/132 cluster regulates B cell development by targeting Sox4. J Exp Med. 2015;212:1679\u201392.","journal-title":"J Exp Med"},{"key":"3300_CR89","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/carcin\/bgr105","volume":"32","author":"S Zhang","year":"2011","unstructured":"Zhang S, Hao J, Xie F, Hu X, Liu C, Tong J, et al. Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Carcinogenesis. 2011;32:1183\u20139.","journal-title":"Carcinogenesis"},{"key":"3300_CR90","doi-asserted-by":"publisher","first-page":"e91827","DOI":"10.1371\/journal.pone.0091827","volume":"9","author":"J You","year":"2014","unstructured":"You J, Li Y, Fang N, Liu B, Zu L, Chang R, et al. MiR-132 suppresses the migration and invasion of lung cancer cells via targeting the EMT regulator ZEB2. PLoS ONE. 2014;9:e91827.","journal-title":"PLoS ONE"},{"key":"3300_CR91","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.immuni.2015.05.017","volume":"42","author":"A Mehta","year":"2015","unstructured":"Mehta A, Zhao JL, Sinha N, Marinov GK, Mann M, Kowalczyk MS, et al. The microRNA-132 and microRNA-212 cluster regulates hematopoietic stem cell maintenance and survival with age by buffering FOXO3 expression. Immunity. 2015;42:1021\u201332.","journal-title":"Immunity"},{"key":"3300_CR92","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/nm.2772","volume":"18","author":"SP Tenbaum","year":"2012","unstructured":"Tenbaum SP, Ord\u00f3\u00f1ez-Mor\u00e1n P, Puig I, Chicote I, Arqu\u00e9s O, Landolfi S, et al. \u03b2-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med. 2012;18:892\u2013901.","journal-title":"Nat Med"},{"key":"3300_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1179101","volume":"14","author":"J Lees","year":"2023","unstructured":"Lees J, Hay J, Moles MW, Michie AM. The discrete roles of individual FOXO transcription factor family members in B-cell malignancies. Front Immunol. 2023;14:1179101.","journal-title":"Front Immunol"},{"key":"3300_CR94","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.cell.2011.07.032","volume":"146","author":"SM Sykes","year":"2011","unstructured":"Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, et al. AKT\/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell. 2011;146:697\u2013708.","journal-title":"Cell"},{"key":"3300_CR95","doi-asserted-by":"publisher","first-page":"103626","DOI":"10.18632\/oncotarget.22093","volume":"8","author":"CY Namasu","year":"2017","unstructured":"Namasu CY, Katzerke C, Br\u00e4uer-Hartmann D, Wurm AA, Gerloff D, Hartmann JU, et al. ABR, a novel inducer of transcription factor C\/EBP\u03b1, contributes to myeloid differentiation and is a favorable prognostic factor in acute myeloid leukemia. Oncotarget. 2017;8:103626\u201339.","journal-title":"Oncotarget"},{"key":"3300_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11452","volume":"7","author":"X Jiang","year":"2016","unstructured":"Jiang X, Hu C, Arnovitz S, Bugno J, Yu M, Zuo Z, et al. miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. Nat Commun. 2016;7:11452.","journal-title":"Nat Commun"},{"key":"3300_CR97","doi-asserted-by":"publisher","first-page":"e0281536","DOI":"10.1371\/journal.pone.0281536","volume":"18","author":"S Cui","year":"2023","unstructured":"Cui S, Chen Y, Guo Y, Wang X, Chen D. Hsa-miR-22-3p inhibits liver cancer cell EMT and cell migration\/ invasion by indirectly regulating SPRY2. PLoS ONE. 2023;18:e0281536.","journal-title":"PLoS ONE"},{"key":"3300_CR98","first-page":"1221","volume":"13","author":"X Yang","year":"2021","unstructured":"Yang X, Su W, Li Y, Zhou Z, Zhou Y, Shan H, et al. MiR-22-3p suppresses cell growth via MET\/STAT3 signaling in lung cancer. Am J Transl Res. 2021;13:1221\u201332.","journal-title":"Am J Transl Res"},{"key":"3300_CR99","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3892\/ijo.2016.3811","volume":"50","author":"J Wang","year":"2017","unstructured":"Wang J, Li Y, Ding M, Zhang H, Xu X, Tang J. Molecular mechanisms and clinical applications of miR-22 in regulating malignant progression in human cancer (Review). Int J Oncol. 2017;50:345\u201355.","journal-title":"Int J Oncol"},{"key":"3300_CR100","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1158\/1078-0432.CCR-10-1800","volume":"17","author":"D Li","year":"2011","unstructured":"Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y, et al. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res. 2011;17:1722\u201330.","journal-title":"Clin Cancer Res"},{"key":"3300_CR101","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/jcp.29065","volume":"235","author":"J Bai","year":"2020","unstructured":"Bai J, Xu J, Zhao J, Zhang R. lncRNA SNHG1 cooperated with miR-497\/miR-195-5p to modify epithelial\u2013mesenchymal transition underlying colorectal cancer exacerbation. J Cell Physiol. 2020;235:1453\u201368.","journal-title":"J Cell Physiol"},{"key":"3300_CR102","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1002\/1878-0261.12581","volume":"13","author":"D-K Chae","year":"2019","unstructured":"Chae D-K, Park J, Cho M, Ban E, Jang M, Yoo YS, et al. MiR-195 and miR-497 suppress tumorigenesis in lung cancer by inhibiting SMURF2-induced TGF-\u03b2 receptor I ubiquitination. Mol Oncol. 2019;13:2663\u201378.","journal-title":"Mol Oncol"},{"key":"3300_CR103","doi-asserted-by":"publisher","first-page":"7109","DOI":"10.2147\/OTT.S183600","volume":"11","author":"W Yu","year":"2018","unstructured":"Yu W, Liang X, Li X, Zhang Y, Sun Z, Liu Y, et al. MicroRNA-195: a review of its role in cancers. Onco Targets Ther. 2018;11:7109\u201323.","journal-title":"Onco Targets Ther"},{"key":"3300_CR104","doi-asserted-by":"publisher","first-page":"55900","DOI":"10.18632\/oncotarget.10152","volume":"7","author":"G Yang","year":"2016","unstructured":"Yang G, Xiong G, Cao Z, Zheng S, You L, Zhang T, et al. miR-497 expression, function and clinical application in cancer. Oncotarget. 2016;7:55900\u201311.","journal-title":"Oncotarget"},{"key":"3300_CR105","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.yexcr.2018.06.026","volume":"370","author":"G Xiao","year":"2018","unstructured":"Xiao G, Li Y, Wang Y, Zhao B, Zou Z, Hou S, et al. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity. Exp Cell Res. 2018;370:254\u201363.","journal-title":"Exp Cell Res"},{"key":"3300_CR106","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.12659\/MSM.900205","volume":"23","author":"P Su","year":"2017","unstructured":"Su P, Wang F, Qi B, Wang T, Zhang S. P53 regulation-association long non-coding RNA (lncRNA PRAL) inhibits cell proliferation by regulation of P53 in human lung cancer. Med Sci Monit. 2017;23:1751\u20138.","journal-title":"Med Sci Monit"},{"key":"3300_CR107","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/hep.28393","volume":"63","author":"CC Zhou","year":"2016","unstructured":"Zhou CC, Yang F, Yuan SX, Ma JZ, Liu F, Yuan JH, et al. Systemic genome screening identifies the outcome associated focal loss of long noncoding RNA PRAL in hepatocellular carcinoma. Hepatology. 2016;63:850\u201363.","journal-title":"Hepatology"},{"key":"3300_CR108","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.7754\/Clin.Lab.2018.171237","volume":"64","author":"H Wang","year":"2018","unstructured":"Wang H, Wang J, Liang CF, Zhou T. Expression of long non-coding RNA PRAL as a potential biomarker for diagnosis in non-small-cell lung cancer patients is associated with the inhibition of cell proliferation and metastasis. Clin Lab. 2018;64:1341\u20138.","journal-title":"Clin Lab"},{"key":"3300_CR109","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.placenta.2020.10.009","volume":"103","author":"J Jiang","year":"2021","unstructured":"Jiang J, Hu H, Chen Q, Zhang Y, Chen W, Huang Q, et al. Long non-coding RNA SNHG29 regulates cell senescence via p53\/p21 signaling in spontaneous preterm birth. Placenta. 2021;103:64\u201371.","journal-title":"Placenta"},{"key":"3300_CR110","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/s41375-023-01923-y","volume":"37","author":"S Liu","year":"2023","unstructured":"Liu S, Zhou J, Ye X, Chen D, Chen W, Lin Y, et al. A novel lncRNA SNHG29 regulates EP300- related histone acetylation modification and inhibits FLT3-ITD AML development. Leukemia. 2023;37:1421\u201334.","journal-title":"Leukemia"},{"key":"3300_CR111","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1016\/j.ymthe.2021.05.012","volume":"29","author":"W Ni","year":"2021","unstructured":"Ni W, Mo H, Liu Y, Xu Y, Qin C, Zhou Y, et al. Targeting cholesterol biosynthesis promotes anti-tumor immunity by inhibiting long noncoding RNA SNHG29-mediated YAP activation. Mol Ther. 2021;29:2995\u20133010.","journal-title":"Mol Ther"},{"key":"3300_CR112","first-page":"1473","volume":"18","author":"F Wang","year":"2018","unstructured":"Wang F, Tian X, Zhou J, Wang G, Yu W, Li Z, et al. A three\u2011lncRNA signature for prognosis prediction of acute myeloid leukemia in patients. Mol Med Rep. 2018;18:1473\u201384.","journal-title":"Mol Med Rep"},{"key":"3300_CR113","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41421-022-00460-9","volume":"8","author":"W Huang","year":"2022","unstructured":"Huang W, Sun YM, Pan Q, Fang K, Chen XT, Zeng ZC, et al. The snoRNA-like lncRNA LNC-SNO49AB drives leukemia by activating the RNA-editing enzyme ADAR1. Cell Discov. 2022;8:117.","journal-title":"Cell Discov"},{"key":"3300_CR114","doi-asserted-by":"publisher","first-page":"107","DOI":"10.17219\/acem\/112608","volume":"29","author":"M Ussowicz","year":"2020","unstructured":"Ussowicz M, Marcel V, Long FNV, Kazanowska B, Diaz JJ, Wo\u0142owiec D. Analysis of the rRNA methylation complex components in pediatric B-cell precursor acute lymphoblastic leukemia: A pilot study. Adv Clin Exp Med. 2020;29:107\u201313.","journal-title":"Adv Clin Exp Med"},{"key":"3300_CR115","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.3934\/mbe.2022112","volume":"19","author":"R Huang","year":"2022","unstructured":"Huang R, Liao X, Li Q. Integrative genomic analysis of a novel small nucleolar RNAs prognostic signature in patients with acute myelocytic leukemia. Math Biosci Eng. 2022;19:2424\u201352.","journal-title":"Math Biosci Eng"},{"key":"3300_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-01056-8","volume":"8","author":"Z-H Huang","year":"2022","unstructured":"Huang Z-H, Du Y-P, Wen J-T, Lu B-F, Zhao Y. snoRNAs: functions and mechanisms in biological processes, and roles in tumor pathophysiology. Cell Death Discovery. 2022;8:259.","journal-title":"Cell Death Discovery"},{"key":"3300_CR117","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jgg.2016.12.004","volume":"44","author":"Y Liu","year":"2017","unstructured":"Liu Y, Sun J, Zhao M. ONGene: A literature-based database for human oncogenes. J Genet Genomics. 2017;44:119\u201321.","journal-title":"J Genet Genomics"},{"key":"3300_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01175-8","volume":"14","author":"A Sekar","year":"2024","unstructured":"Sekar A, Griffin R, Parikh SA, Genovese G, Robinson DP, Norman AD, et al. Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL). Blood Cancer J. 2024;14:193.","journal-title":"Blood Cancer J"},{"key":"3300_CR119","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1182\/bloodadvances.2022009040","volume":"7","author":"R Griffin","year":"2023","unstructured":"Griffin R, Wiedmeier-Nutor JE, Parikh SA, McCabe CE, O\u2019Brien DR, Boddicker NJ, et al. Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL. Blood Adv. 2023;7:3169\u201379.","journal-title":"Blood Adv"},{"key":"3300_CR120","doi-asserted-by":"publisher","first-page":"5690","DOI":"10.3390\/cancers15235690","volume":"15","author":"G Tang","year":"2023","unstructured":"Tang G, Wu Y, Lin P, Toruner GA, Hu S, Li S, et al. Cytogenetic profile in monoclonal gammopathy of undetermined significance, smoldering and symptomatic multiple myeloma: A Study of 1087 patients with highly purified plasma cells. Cancers. 2023;15:5690.","journal-title":"Cancers"},{"key":"3300_CR121","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.20.00437","volume":"38","author":"M Bustoros","year":"2020","unstructured":"Bustoros M, Sklavenitis-Pistofidis R, Park J, Redd R, Zhitomirsky B, Dunford AJ, et al. Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression. J Clin Oncol. 2020;38:2380\u20139.","journal-title":"J Clin Oncol"},{"key":"3300_CR122","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1053\/gast.2002.36051","volume":"123","author":"M Hermsen","year":"2002","unstructured":"Hermsen M, Postma C, Baak J, Weiss M, Rapallo A, Sciutto A, et al. Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. Gastroenterology. 2002;123:1109\u201319.","journal-title":"Gastroenterology"},{"key":"3300_CR123","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/leu.2014.297","volume":"29","author":"J Malcikova","year":"2015","unstructured":"Malcikova J, Stano-Kozubik K, Tichy B, Kantorova B, Pavlova S, Tom N, et al. Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. Leukemia. 2015;29:877\u201385.","journal-title":"Leukemia"},{"key":"3300_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0191-y","volume":"9","author":"A Lakshman","year":"2019","unstructured":"Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, et al. Natural history of multiple myeloma with de novo del(17p). Blood Cancer J. 2019;9:32.","journal-title":"Blood Cancer J"},{"key":"3300_CR125","first-page":"5331","volume":"16","author":"L Zhang","year":"2018","unstructured":"Zhang L, Liu D, Tang B, Xu A, Huang H, Su Y, et al. MicroRNA-324-5p suppresses the migration and invasion of MM cells by inhibiting the SCF(\u03b2-TrCP) E3 ligase. Oncol Lett. 2018;16:5331\u20138.","journal-title":"Oncol Lett"},{"key":"3300_CR126","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1158\/0008-5472.CAN-20-1890","volume":"81","author":"Z Dong","year":"2021","unstructured":"Dong Z, Yeo KS, Lopez G, Zhang C, Dankert Eggum EN, Rokita JL, et al. GAS7 deficiency promotes metastasis in MYCN-driven neuroblastoma. Cancer Res. 2021;81:2995\u20133007.","journal-title":"Cancer Res"},{"key":"3300_CR127","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28941-6","volume":"8","author":"R Jansen","year":"2018","unstructured":"Jansen R, Moehlendick B, Bartenhagen C, T\u00f3th C, Lehwald N, Stoecklein NH, et al. ACGH detects distinct genomic alterations of primary intrahepatic cholangiocarcinomas and matched lymph node metastases and identifies a poor prognosis subclass. Sci Rep. 2018;8:10637.","journal-title":"Sci Rep"},{"key":"3300_CR128","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3748\/wjg.v8.i5.769","volume":"8","author":"LX Qin","year":"2002","unstructured":"Qin LX. Chromosomal aberrations related to metastasis of human solid tumors. World J Gastroenterol. 2002;8:769\u201376.","journal-title":"World J Gastroenterol"},{"key":"3300_CR129","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1182\/blood-2009-05-224071","volume":"114","author":"T Zenz","year":"2009","unstructured":"Zenz T, H\u00e4be S, Denzel T, Mohr J, Winkler D, B\u00fchler A, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009;114:2589\u201397.","journal-title":"Blood"},{"key":"3300_CR130","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1038\/s41375-021-01295-1","volume":"35","author":"C Saygin","year":"2021","unstructured":"Saygin C, Hu E, Zhang P, Sher S, Lozanski A, Doong TJ, et al. Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq. Leukemia. 2021;35:3406\u201320.","journal-title":"Leukemia"},{"key":"3300_CR131","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3324\/haematol.2017.168005","volume":"102","author":"M Merz","year":"2017","unstructured":"Merz M, Jauch A, Hielscher T, Mai EK, Seckinger A, Hose D, et al. Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. Haematologica. 2017;102:1432\u20138.","journal-title":"Haematologica"},{"key":"3300_CR132","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1038\/s41375-020-01096-y","volume":"35","author":"J Croft","year":"2021","unstructured":"Croft J, Ellis S, Sherborne AL, Sharp K, Price A, Jenner MW, et al. Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia. 2021;35:2043\u201353.","journal-title":"Leukemia"},{"key":"3300_CR133","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.3324\/haematol.2017.168872","volume":"102","author":"S Thanendrarajan","year":"2017","unstructured":"Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, et al. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017;102:e364\u2013e7.","journal-title":"Haematologica"},{"key":"3300_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06783-7","volume":"15","author":"Y Guo","year":"2024","unstructured":"Guo Y, Wu H, Wiesm\u00fcller L, Chen M. Canonical and non-canonical functions of p53 isoforms: potentiating the complexity of tumor development and therapy resistance. Cell Death Dis. 2024;15:412.","journal-title":"Cell Death Dis"},{"key":"3300_CR135","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.trecan.2021.09.002","volume":"8","author":"DA Lukow","year":"2022","unstructured":"Lukow DA, Sheltzer JM. Chromosomal instability and aneuploidy as causes of cancer drug resistance. Trends Cancer. 2022;8:43\u201353.","journal-title":"Trends Cancer"},{"key":"3300_CR136","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40425-019-0509-0","volume":"7","author":"C Bagacean","year":"2019","unstructured":"Bagacean C, Tempescul A, Ternant D, Banet A, Douet-Guilbert N, Bordron A, et al. 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia. J Immunother Cancer. 2019;7:22.","journal-title":"J Immunother Cancer"},{"key":"3300_CR137","first-page":"471","volume":"14","author":"L Roncuzzi","year":"2005","unstructured":"Roncuzzi L, Brognara I, Baiocchi D, Amadori D, Gasperi-Campani A. Loss of heterozygosity at 17p13.3-ter, distal to TP53, correlates with negative hormonal phenotype in sporadic breast cancer. Oncol Rep. 2005;14:471\u20134.","journal-title":"Oncol Rep"},{"key":"3300_CR138","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.4161\/cc.5.10.2805","volume":"5","author":"SC Cunningham","year":"2006","unstructured":"Cunningham SC, Gallmeier E, Hucl T, Dezentje DA, Abdelmohsen K, Gorospe M, et al. Theoretical proposal: Allele dosage of MAP2K4\/MKK4 could rationalize frequent 17p loss in diverse human cancers. Cell Cycle. 2006;5:1090\u20133.","journal-title":"Cell Cycle"},{"key":"3300_CR139","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1158\/0008-5472.CAN-13-2941","volume":"74","author":"CC Davies","year":"2014","unstructured":"Davies CC, Harvey E, McMahon RF, Finegan KG, Connor F, Davis RJ, et al. Impaired JNK signaling cooperates with KrasG12D expression to accelerate pancreatic ductal adenocarcinoma. Cancer Res. 2014;74:3344\u201356.","journal-title":"Cancer Res"},{"key":"3300_CR140","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1158\/1535-7163.MCT-13-0629","volume":"13","author":"W Wang","year":"2014","unstructured":"Wang W, Wang YQ, Meng T, Yi JM, Huan XJ, Ma LP, et al. MCL-1 degradation mediated by JNK activation via MEKK1\/TAK1-MKK4 contributes to anticancer activity of new tubulin inhibitor MT189. Mol Cancer Ther. 2014;13:1480\u201391.","journal-title":"Mol Cancer Ther"},{"key":"3300_CR141","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3324\/haematol.2018.193615","volume":"103","author":"AR Mato","year":"2018","unstructured":"Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018;103:1511\u20137.","journal-title":"Haematologica"},{"key":"3300_CR142","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.neo.2020.09.001","volume":"22","author":"Y Hou","year":"2020","unstructured":"Hou Y, Hou L, Liang Y, Zhang Q, Hong X, Wang Y, et al. The p53-inducible CLDN7 regulates colorectal tumorigenesis and has prognostic significance. Neoplasia. 2020;22:590\u2013603.","journal-title":"Neoplasia"},{"key":"3300_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13420-x","volume":"10","author":"S Xu","year":"2019","unstructured":"Xu S, Zhan M, Jiang C, He M, Yang L, Shen H, et al. Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer. Nat Commun. 2019;10:5492.","journal-title":"Nat Commun"},{"key":"3300_CR144","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14344","volume":"520","author":"L Jiang","year":"2015","unstructured":"Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520:57\u201362.","journal-title":"Nature"},{"key":"3300_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2022.100058","volume":"103","author":"X Li","year":"2023","unstructured":"Li X, Xiong W, Wang Y, Li Y, Cheng X, Liu W. p53 activates the lipoxygenase activity of ALOX15B via inhibiting SLC7A11 to induce ferroptosis in bladder cancer cells. Lab Invest. 2023;103:100058.","journal-title":"Lab Invest"},{"key":"3300_CR146","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09722-x","volume":"22","author":"J Li","year":"2022","unstructured":"Li J, Tang LL, Ma J. Survival-related indicators ALOX12B and SPRR1A are associated with DNA damage repair and tumor microenvironment status in HPV 16-negative head and neck squamous cell carcinoma patients. BMC Cancer. 2022;22:714.","journal-title":"BMC Cancer"},{"key":"3300_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-021-00304-3","volume":"10","author":"X Yang","year":"2021","unstructured":"Yang X, Liu J, Wang C, Cheng KK, Xu H, Li Q, et al. miR-18a promotes glioblastoma development by down-regulating ALOXE3-mediated ferroptotic and anti-migration activities. Oncogenesis. 2021;10:15.","journal-title":"Oncogenesis"},{"key":"3300_CR148","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41556-019-0305-6","volume":"21","author":"B Chu","year":"2019","unstructured":"Chu B, Kon N, Chen D, Li T, Liu T, Jiang L, et al. ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nat Cell Biol. 2019;21:579\u201391.","journal-title":"Nat Cell Biol"},{"key":"3300_CR149","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1111\/cas.13380","volume":"108","author":"R Shintoku","year":"2017","unstructured":"Shintoku R, Takigawa Y, Yamada K, Kubota C, Yoshimoto Y, Takeuchi T, et al. Lipoxygenase-mediated generation of lipid peroxides enhances ferroptosis induced by erastin and RSL3. Cancer Sci. 2017;108:2187\u201394.","journal-title":"Cancer Sci"},{"key":"3300_CR150","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01168-8","volume":"19","author":"H Zhang","year":"2020","unstructured":"Zhang H, Deng T, Liu R, Ning T, Yang H, Liu D, et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer. 2020;19:43.","journal-title":"Mol Cancer"},{"key":"3300_CR151","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.1002\/jcp.29375","volume":"235","author":"HH Kazan","year":"2020","unstructured":"Kazan HH, Urfali-Mamatoglu C, Yalcin GD, Bulut O, Sezer A, Banerjee S, et al. 15-LOX-1 has diverse roles in the resensitization of resistant cancer cell lines to doxorubicin. J Cell Physiol. 2020;235:4965\u201378.","journal-title":"J Cell Physiol"},{"key":"3300_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-023-00451-9","volume":"12","author":"L Qi","year":"2023","unstructured":"Qi L, Pan X, Chen X, Liu P, Chen M, Zhang Q, et al. COX-2\/PGE2 upregulation contributes to the chromosome 17p-deleted lymphoma. Oncogenesis. 2023;12:5.","journal-title":"Oncogenesis"},{"key":"3300_CR153","doi-asserted-by":"publisher","first-page":"71378","DOI":"10.18632\/oncotarget.12110","volume":"7","author":"J Liu","year":"2016","unstructured":"Liu J, Chen G, Pelicano H, Liao J, Huang J, Feng L, et al. Targeting p53-deficient chronic lymphocytic leukemia cells in vitro and in vivo by ROS-mediated mechanism. Oncotarget. 2016;7:71378\u201389.","journal-title":"Oncotarget"},{"key":"3300_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106583","volume":"187","author":"X Cui","year":"2023","unstructured":"Cui X, Han L, Cui L, Fu G, Liu E, Wang D, et al. Immune index: A gene and cell prognostic signature for immunotherapy response prediction in hepatocellular carcinoma. Pharmacol Res. 2023;187:106583.","journal-title":"Pharmacol Res"},{"key":"3300_CR155","doi-asserted-by":"crossref","unstructured":"Singh RK, Jones RJ, Shirazi F, Qin L, Zou J, Hong S, et al. Novel anti-B-cell maturation antigen alpha-amanitin antibody-drug conjugate HDP-101 shows superior activity to belantamab mafodotin and enhanced efficacy in deletion 17p myeloma models. Res Sq [Preprint]. 2024 Jan:rs.3.rs-3843028.","DOI":"10.21203\/rs.3.rs-3843028\/v1"},{"key":"3300_CR156","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1158\/1535-7163.MCT-20-0287","volume":"20","author":"V Figueroa-Vazquez","year":"2021","unstructured":"Figueroa-Vazquez V, Ko J, Breunig C, Baumann A, Giesen N, P\u00e1lfi A, et al. HDP-101, an anti-BCMA antibody-drug conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells. Mol Cancer Ther. 2021;20:367\u201378.","journal-title":"Mol Cancer Ther"},{"key":"3300_CR157","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1182\/blood-2023-182480","volume":"142","author":"MS Raab","year":"2023","unstructured":"Raab MS, Kaufman JL, Richard S, Grosicki S, Takacs I, Strassz A, et al. Hdp-101, an anti-BCMA antibody-drug conjugate with a novel payload amanitin in patients with relapsed multiple myeloma, initial findings of the first in human study. Blood. 2023;142:3334.","journal-title":"Blood"},{"key":"3300_CR158","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1158\/0008-5472.CAN-22-0698","volume":"82","author":"KA Altwegg","year":"2022","unstructured":"Altwegg KA, Viswanadhapalli S, Mann M, Chakravarty D, Krishnan S, Liu Z, et al. A first-in-class inhibitor of ER coregulator PELP1 targets ER+ Breast Cancer. Cancer Res. 2022;82:3830\u201344.","journal-title":"Cancer Res"},{"key":"3300_CR159","doi-asserted-by":"publisher","first-page":"50930","DOI":"10.1074\/jbc.M406831200","volume":"279","author":"YB Choi","year":"2004","unstructured":"Choi YB, Ko JK, Shin J. The transcriptional corepressor, PELP1, recruits HDAC2 and masks histones using two separate domains. J Biol Chem. 2004;279:50930\u201341.","journal-title":"J Biol Chem"},{"key":"3300_CR160","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1200\/JCO.2011.35.9695","volume":"30","author":"AR Pettitt","year":"2012","unstructured":"Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, et al. Alemtuzumab in combination with methylprednisolone Is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: Final results of the National Cancer Research Institute CLL206 trial. J Clin Oncol. 2012;30:1647\u201355.","journal-title":"J Clin Oncol"},{"key":"3300_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2023.113634","volume":"429","author":"C Yuan","year":"2023","unstructured":"Yuan C, Yuan M, Li W, Cheng H, Luo J, Zhang Q, et al. The STAT3 inhibitor stattic overcome bortezomib-resistance in multiple myeloma via decreasing PSMB6. Exp Cell Res. 2023;429:113634.","journal-title":"Exp Cell Res"},{"key":"3300_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2020.115158","volume":"403","author":"L Gao","year":"2020","unstructured":"Gao L, Xue B, Xiang B, Liu KJ. Arsenic trioxide disturbs the LIS1\/NDEL1\/dynein microtubule dynamic complex by disrupting the CLIP170 zinc finger in head and neck cancer. Toxicol Appl Pharmacol. 2020;403:115158.","journal-title":"Toxicol Appl Pharmacol"},{"key":"3300_CR163","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10577-023-09735-7","volume":"31","author":"MA Truong","year":"2023","unstructured":"Truong MA, Can\u00e9-Gasull P, Lens SMA. Modeling specific aneuploidies: from karyotype manipulations to biological insights. Chromosome Res. 2023;31:25.","journal-title":"Chromosome Res"},{"key":"3300_CR164","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.79895","volume":"11","author":"S Mansouri","year":"2022","unstructured":"Mansouri S, Heylmann D, Stiewe T, Kracht M, Savai R. Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity. eLife. 2022;11:e79895.","journal-title":"eLife"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03300-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03300-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03300-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T12:01:10Z","timestamp":1741003270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03300-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":164,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,3,24]]}},"alternative-id":["3300"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03300-8","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"14 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests financial or otherwise Preparation of this article was supported by a Northwest Cancer Research UK and Bloom Appeal (NWCRTBA2021.02) grant funding to AC, MG, ARP, NK and JRS.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}